Compare ARK Genomic Revolution ETF (ARKG) vs Target Corporation (TGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Target Corporation — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Target Corporation trades at $135.7 (market cap $61.38B). The key difference: Target Corporation pays a 3.43% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | TGT | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $141.19 |
52-Week Low | $23.09 | $83.68 |
Market Cap | — | $61.38B |
Enterprise Value | — | $76.68B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Target Corporation (TGT) trades at $135.13, up 2.19% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a P/E of 17.85, ROE of 22.02%, and positive cash flow trends. Recent corporate restructuring aims to streamline operations while maintaining dividend payments.
Target presents a balanced investment case with solid profitability and analyst consensus near current levels. Upside potential exists toward the $137 price target, though competitive pressures and margin compression remain key risks. The stock offers stability with dividend income but faces retail sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
